Understanding the Switchbacks: The Impact of Direct Antivirals on the Minimization of Hepatitis C Virus Recurrence After Transplantation
|
|
- Margaret Park
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 18:S47-S51, 2012 SUPPLEMENT Understanding the Switchbacks: The Impact of Direct Antivirals on the Minimization of Hepatitis C Virus Recurrence After Transplantation David Mutimer Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom and NIHR Birmingham Liver Biomedical Research Unit, Birmingham, United Kingdom Key Points 1. Interferon (IFN) and ribavirin can be used in select patients before or after liver transplantation, and they can reduce the risk of recurrence or effect a cure in these settings. 2. Currently licensed direct-acting antiviral drugs are used with IFN and ribavirin, so the safety and tolerability of triple therapy will be worse than those of double therapy in pretransplant and posttransplant settings. 3. Drug-drug interactions [exemplified by the interactions of protease inhibitors (PIs) with tacrolimus and cyclosporine] and the need for dose modifications (exemplified by the need to modify ribavirin doses in patients with renal dysfunction) challenge the safe use of antiviral drugs after transplantation. 4. Experience with the use of human immunodeficiency virus PIs and emerging data about hepatitis C virus (HCV) PIs show that this class of drugs can be used with care after transplantation. 5. Attempts to prevent HCV graft infections through the use of HCV immunoglobulin immediately after transplantation have been largely unsuccessful. 6. The blockade of cell surface HCV receptors with antibodies or small molecules appears to limit HCV cell entry in vivo and in a mouse model, and this may suggest a novel approach to limiting HCV recurrence at the time of transplantation. Liver Transpl 18:S47 S51, VC 2012 AASLD. Received May 1, 2012; accepted August 6, Until recently, interferon (IFN) and ribavirin were the only antiviral drugs licensed to treat hepatitis C virus (HCV). The first direct-acting antivirals (DAAs) to be licensed are telaprevir and boceprevir, which are specific inhibitors of the HCV-encoded protease. Although these protease inhibitors (PIs) may have some activity against other HCV genotypes, they are licensed only for the treatment of HCV genotype 1 (G1) infections. Published phase 3 studies have shown that the addition of a PI to IFN and ribavirin increases the rate of sustained virological response (SVR) for treatment-naive and treatment-experienced patients (including patients with established but well-compensated cirrhosis). 1 These studies also show that the inclusion of a PI in the treatment regimen is associated with an enhanced rate of early serum HCV RNA negativity, and early negativity is associated with high rates of SVR and with the opportunity to abbreviate the course of treatment. The phase 3 studies of telaprevir and boceprevir have included a minority of patients with established cirrhosis. At this year s annual meeting of the European Association for the Study of the Liver, an interim analysis was presented for a cohort of patients with cirrhosis who received either telaprevir- or boceprevir-containing triple therapy. 2 High Abbreviations: CNI, calcineurin inhibitor; DAA, direct-acting antiviral; DDI, drug-drug interaction; G1, genotype 1; G2, genotype 2; G3, genotype 3; G4, genotype 4; HBV, hepatitis B virus; HCIG, hepatitis C immunoglobulin; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; LT, liver transplantation; NA, not applicable; PCR, polymerase chain reaction; PEG-IFN, pegylated interferon; PI, protease inhibitor; SVR, sustained virological response. Potential conflict of interest: Nothing to report. Address reprint requests to David Mutimer, M.D., Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Nuffield House, 3rd Floor, Birmingham B15 2TH, United Kingdom. Telephone: ; Fax: ; david.mutimer@uhb.nhs.uk DOI /lt View this article online at wileyonlinelibrary.com. LIVER TRANSPLANTATION.DOI /lt. Published on behalf of the American Association for the Study of Liver Diseases Liver Transplantation, Vol 18, No 11, Suppl 2 (November), 2012: pp S47-S51 S47
2 S48 MUTIMER LIVER TRANSPLANTATION, November 2012 rates of serious adverse events and treatment discontinuation were observed. Patients with cirrhosis have much to gain from viral eradication, but physicians must be alert to the risks of antiviral treatment (either dual or triple therapy) given to patients with advanced liver disease. Indeed, there are no published data describing the efficacy and safety of triple therapy in patients with very advanced disease, such as those with liver failure on the transplant waiting list. It seems inevitable that these PIs and other DAAs in the development pipeline will transform the outcomes of patients with advanced liver disease and patients with HCV infections after transplantation. These expectations are based on the evidence of the benefits of successful antiviral treatment with IFN and ribavirin without PIs in the pretransplant and posttransplant settings. The successful antiviral treatment of the patient with well-compensated cirrhosis dramatically reduces the future risk of hepatic decompensation and also reduces the risk of the development of primary liver cancer. 3 The patient with more advanced cirrhosis at the baseline poses a greater challenge, and IFN-based treatment regimens are poorly tolerated. However, the successful treatment of decompensated cirrhosis may also improve clinical outcomes and reduce the need for transplantation. 4 In most published studies, the aims of antiviral treatment for advanced disease have been the achievement of serum HCV negativity and the reduction of the risk of posttransplant HCV recurrence 4-9 (see Mutimer and Lok 10 for a review; see also Table 1). These studies suggest that serum polymerase chain reaction (PCR) negativity during antiviral therapy at the time of transplantation decreases the risk of posttransplant HCV recurrence, and this should in turn be associated with superior graft and patient outcomes. This leads to the proposal of a potentially important role for DAA-containing antiviral regimens in the peritransplant management of HCV patients. For G1- infected patients with well-compensated disease and with primary liver cancer as the indication for transplantation, triple therapy with IFN, ribavirin, and either boceprevir or telaprevir can achieve serum PCR negativity at an earlier stage of treatment and in a higher proportion of treated patients. Such protocols may be easier to implement for patients who have a living donor because the timing of the transplant operation can be reconciled with the course of the antiviral treatment and with the results of serum HCV testing. In the future, IFN-free regimens for all HCV genotypes may transform the management of patients with advanced disease, including those on our transplant waiting lists. HCV recurrence in the transplanted liver is associated with impaired graft and patient survival after transplantation. There is an abundance of published series describing the outcomes of dual therapy with IFN and ribavirin for HCV after liver transplantation (LT; see Roche and Samuel 11 for a review). In highly select cohorts, investigators have reported that SVR can be achieved in 30% of treated patients. Obstacles TABLE 1. Studies of HCV Antiviral Therapy in Patients With Decompensated Cirrhosis SVR After LT (n/n) PCR-Negative Before LT (n/n) PCR-Negative at the End of Treatment (n/n) SVR (n/n) Patients Study Treatment Regimen Duration (n) 20 NA NA 12/20 4/20 Thomas et al. 8 5 MU of IFNa2b daily 14 months ( months)* NA NA Iacobellis et al. 4 PEG-IFNa2b/ribavirin 24 weeks (43% for G2/G3 and 7% for G1/G4) NA NA Iacobellis et al. 9 PEG-IFNa2b/ribavirin weeks (57% for G2/G3 and 16% for G1/G4) 12 weeks 30 NA NA 9/30 6/30 (2-30 weeks) weeks /47 12/47 Forns et al. 5 3 MU of IFNa2b daily/ribavirin Everson et al. 7 IFNa2b/ribavirin (low accelerating dose regimen) Carrion et al. 6 PEG-IFNa2a/ribavirin 15 weeks 51 NA NA 15/43 # 10/43 # (1-57 weeks) NOTE: Some studies were specifically designed to treat patients until the time of transplantation, so the duration of treatment was quite variable. *The data are presented as the mean and the range. The data are presented as the median and the range. In this study, 47 of the original 124 patients underwent LT. # In this study 43 patients underwent LT.
3 LIVER TRANSPLANTATION, Vol. 18, No. 11, 2012 MUTIMER S49 to successful treatment in this setting include low baseline hemoglobin, white cell, and platelet counts and chronic impairment of renal function. In addition, some patients have already demonstrated poor sensitivity to IFN-containing regimens administered before transplantation. Thus, published series have included a minority of transplant patients with HCV, and the results of treatment have been inferior to the results achieved in the nontransplant setting. Nevertheless, a significant number of patients have been cured by dual therapy, and the response rates for patients with more favorable HCV genotypes are acceptable. In addition, it has been shown that successful treatment is associated with improved graft and patient survival in the posttransplant setting. 12 The availability of telaprevir and boceprevir may improve the chance of a cure for select transplant patients. However, the tolerability of triple therapy is worse than that of dual therapy. The addition of a PI is associated with additional side effects, including anemia and bone marrow suppression. Also, PIs have significant potential drug-drug interactions (DDIs), particularly with drugs that are substrates of cytochrome p450, such as tacrolimus and cyclosporine [calcineurin inhibitors (CNIs)]. The potentially troublesome interactions of PI treatments with these immunosuppressive drugs have previously been described for human immunodeficiency virus (HIV) PIs in the transplant setting. 13 Many transplant units have experience with the transplantation of HIV-positive patients and with the adjustments of tacrolimus and cyclosporine administration in that context. The impact of telaprevir on the metabolism of tacrolimus and cyclosporine has been demonstrated in healthy volunteers, and appropriate experience and caution will be prerequisites for the safe and effective use of HCV PIs in transplant patients. 14,15 The coadministration of PIs with tacrolimus or cyclosporine dramatically reduces the metabolism of those drugs and demands immediate reductions of the doses and frequencies of the immunosuppressive drugs. Despite the challenge, appropriate dose adjustments can be made, and patients can be treated without the development of drug toxicity (usually reflected by renal dysfunction) or suboptimal immunosuppression (causing rejection). The reduction of CNI exposure can be achieved by the reduction of the daily dose and/or the dosing frequency. It is my preference to reduce the dosing frequency and to administer small doses (0.5 or 1 mg of tacrolimus) according to frequently measured CNI blood levels. For instance, the patient described in Fig. 1 required only eight 1-mg doses of tacrolimus during a 12-week period of telaprevir therapy, with the interval between consecutive doses ranging from 6 to 14 days (median ¼ 9 days). The figure shows that levels can be maintained within the desired range and without the development of significant renal dysfunction. For the PI-taking HIV patient, however, the challenges are largely confined to the time of the PI s introduction after transplantation. Thereafter, both Figure 1. This patient received telaprevir-containing triple therapy for recurrent HCV after transplantation. The graph shows his blood tacrolimus and serum creatinine levels during the 12 weeks of triple therapy. Before the treatment (not shown on the graph), he required tacrolimus at 1 mg/day to maintain a trough level of 5 to 10. During the treatment, he required only eight 1-mg doses to maintain that blood level. After the telaprevir component of the antiviral treatment was stopped, the patient s tacrolimus levels fell promptly (not shown on the graph), and he required a prompt increase in the tacrolimus dose to 3 mg/day to maintain blood levels. the CNI and the PI are taken indefinitely, so substantial adjustments of the CNI dose should not be required. For the HCV PI-containing regimen, the duration of the PI administration is finite. As a result, additional significant changes to the CNI dose will be required at the time of the conclusion of the PI treatment. PI withdrawal restores p450 function, and this demands an immediate increase in the CNI dose in order to maintain therapeutic drug levels. 16 Thus, for DAAs that affect p450 metabolism, the HCV patient can be exposed to the risk of DDIs at both the commencement and conclusion of therapy. Frequent monitoring of CNI levels is essential. Despite concerns about the risks of these DDIs, there is emerging experience with the use of triple therapy in the posttransplant setting. Indeed, Coilly et al. 17 presented an interim analysis of a cohort of transplant patients who received triple therapy (including either telaprevir or boceprevir) for recurrent HCV infections. The key observations were that (1) a high proportion (approximately 70%) of treated patients achieved serum HCV RNA negativity during the first 4 to 8 weeks of treatment, (2) erythropoietin and transfusion were frequently required, and (3) the interaction of the PI with cyclosporine and tacrolimus was manageable (without the development of drug toxicity). It is inevitable that the emerging and as yet unlicensed DAAs will be used with enthusiasm in the posttransplant patient. 18 Some of these drugs will be metabolized, and others will rely principally on renal elimination. When these drugs are used in appropriately selected patients with caution, it is likely that SVR rates will be enhanced. Safe administration will demand informative data and familiarity with DDIs
4 S50 MUTIMER LIVER TRANSPLANTATION, November 2012 and/or dose modifications in the setting of renal dysfunction. In summary, a conventional approach to the use of DAA drugs for HCV will involve the application of treatment regimens in waiting-list patients and in patients with established chronic infections after transplantation. As an alternative or possibly as a complement to the early introduction of DAA treatment, attempts to limit graft reinfection in the early posttransplant period might also be made. Similarly to hepatitis B immunoglobulin, which has been successfully used for transplant patients with hepatitis B virus (HBV), hepatitis C immunoglobulin (HCIG) has been used for HCV patients. Two informative studies, one using a human plasma derived product 19 and the other using a human monoclonal antibody, 20 have been published. In both studies, the immunoglobulin treatment was given according to algorithms similar to those used for hepatitis B immunoglobulin. Each study monitored the impact of the HCIG treatment on the evolution of HCV antibodies and HCV RNA measurements. The administration of the plasma product at a high dose seemed to have a measurable though short-lived effect on serum HCV antibody levels, but there was no discernable impact on posttransplant HCV RNA titers. The administration of monoclonal HCIG at a high dose was also associated with a measurable rise in serum antibody titers and with a measurable reduction of serum viral titers. The impact of HCIG on serum viral titers was observed only with high doses and during the early posttransplant period with more intensive administration. Central to the assessment of the impact of HCIG treatment on HCV recurrence is an understanding of the observed kinetics of serum HCV RNA in the early posttransplant period. For instance, in the study by Davis et al., 19 a single treated patient was serum PCR negative on days 7 and 14 after transplantation, but the titer rose rapidly thereafter. It is recognized that this pattern with very low titers during the first posttransplant week can be observed for a proportion of transplant patients in the absence of any treatment to ameliorate the recurrence of infection. 21 Studies of viral kinetics after transplantation have demonstrated significant variations The following pattern has been established. The HCV titer usually declines rapidly during the reperfusion phase of the transplant operation, and this possibly reflects the immediate uptake of the circulating virus by the newly implanted liver mass. Viral titers continue to decline for the majority of patients and achieve nadir values 24 to 48 hours after transplantation. Thereafter, the rate of the rise of serum viral titers varies greatly. For a proportion of patients, titers rise rapidly to reach or exceed pretransplant values within a week of transplantation. For others, titers persist at relatively low levels during the first posttransplant week or longer and then rise to reach or exceed pretransplant levels before 4 weeks have elapsed. Thus, attempts to prevent or modify the process of graft reinfection need to incorporate careful and frequent measurements of HCV titers, and their interpretation needs to consider the heterogeneity of the kinetic patterns of serum HCV titers in this setting. Attempts to prevent HCV graft reinfection need to consider the biology of HCV entry into hepatocytes. There have been significant developments in our understanding of this process (as reviewed by Timpe and McKeating 24 ). The process is complex and involves the interaction of the virus (and lipoviral particles) with cell surface molecules, including low-density lipoprotein receptor, heparan sulfate proteoglycans, CD81, scavenger receptor B1, claudin 1, and occludin. In addition to an attempted blockade of virus-cell interactions through the use of putative neutralizing antibodies (ie, HCIG), some of these molecules might present therapeutic targets for preventing or reducing the infection of the graft in the early posttransplant period. For instance, Meuleman et al. 25,26 used the urokinase plasminogen activator/severe combined immunodeficient mouse to evaluate the effects of receptor blockade on HCV infection. Administered to the mouse before HCV inoculation, anti-cd81 or anti scavenger receptor B1 monoclonal antibodies could prevent HCV infection. Thus, in addition to targeting HCV and its components, potential approaches to the prevention and treatment of graft infections might explore the potential of specific antibodies or small molecules that target human cellular receptors for the virus. Such studies in humans are underway. In conclusion, we are just entering the era of DAAs for the treatment of HCV patients. The use of DAAs in the noncirrhotic population should eventually diminish the number of patients who develop complications requiring LT. This will be an important step in reducing the overall demand for donor organs and in bridging the gap between the organ supply and demand. In addition, the development of DAA protocols to prevent graft reinfection will represent a major advance in our management of patients who cannot avoid transplantation. In the same way that protocols for the prevention of HBV graft infections transformed the outcomes of HBV patients, the prevention of HCV graft reinfection will improve graft and patient survival. For select patients with established HCV G1 graft infections, the availability of boceprevir and telaprevir represents an opportunity. Drugs in the development pipeline will soon provide opportunities for a higher proportion of patients, including those with non-1 genotypes. The major challenge will be to use the drugs safely in this setting, and particular attention to drug interactions and dosing will be essential. REFERENCES 1. Rowe IA, Mutimer DJ. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011;343: d Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) [abstract]. J Hepatol 2012; 56(suppl 2):S4.
5 LIVER TRANSPLANTATION, Vol. 18, No. 11, 2012 MUTIMER S51 3. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39: Carrion JA, Martínez-Bauer E, Crespo G, Ramírez S, Perez-del-Pulgar S, García-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCVinfected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50: Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42: Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9: Iacobellis A, Siciliano M, Annicchiarico BE, Valvano MR, Niro GA, Accadia L, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009;30: Mutimer DJ, Lok A. Management of HBV- and HCVinduced end stage liver disease. Gut 2012;61(suppl 1): i59-i Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012;32(suppl 1): Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005;5: Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007;7: Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54: Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents a potentially lethal cocktail. Hepatology 2011;54: Oo YH, Mutimer DJ. Rapid recovery of CYP3A4 following protease inhibitors withdrawal in post liver transplant patients. Liver Transpl 2012;18: Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. J Hepatol 2012;56(suppl 2):S Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012;18: Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al.; for Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11: Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12: Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006;12: Dragun J, Perez-Del-Pulgar S, Crespo G, Ramírez S, Coto-Llerena M, Mensa L, et al. Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. Am J Transplant 2011;11: Timpe JM, McKeating JA. Hepatitis C virus entry: possible targets for therapy. Gut 2008;57: Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48: Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012;55:
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationTreatment of Liver Transplant Recipients Who Have Chronic Hepatitis C Virus Infection
Lecture Treatment of Liver Transplant Recipients Who Have Chronic Hepatitis C Virus Infection Murat Korkmaz Abstract Chronic hepatitis C virus infection is the most common cause of chronic liver disease
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationTelaprevir-Based Triple Therapy in Liver Transplant Patients With Hepatitis C Virus: A 12-Week Pilot Study Providing Safety and Efficacy Data
LIVER TRANSPLANTATION 18:1464-1470, 2012 ORIGINAL ARTICLE Telaprevir-Based Triple Therapy in Liver Transplant Patients With Hepatitis C Virus: A 12-Week Pilot Study Providing Safety and Efficacy Data Christoph
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationSafety and Efficacy of Simeprevir Plus Sofosbuvir With or Without Ribavirin in Patients With Decompensated Genotype 1 Hepatitis C Cirrhosis
LIVER TRANSPLANTATION 22:281 286, 2016 ORIGINAL ARTICLE Safety and Efficacy of Simeprevir Plus Sofosbuvir With or Without Ribavirin in Patients With Decompensated Genotype 1 Hepatitis C Cirrhosis Apurva
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationDirect-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
Editorial Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo Artificial Organ and Transplantation
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationReview Article Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis
Gastroenterology Research and Practice Volume 215, Article ID 2632, 8 pages http://dx.doi.org/1.1155/215/2632 Review Article Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation:
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationHCV Therapy in Liver Transplant Candidate
PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance
More informationCase Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD
More informationIs Treatment cost effective HCV and Organ Transplantation
Is Treatment cost effective HCV and Organ Transplantation Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Barcelona 2016 Disclosures: BoJo Pharma support: AbbVie/Achillion/ Astellas/
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationAccepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?)
Accepted Manuscript Letter to the Editor Reply to: From the CUPIC study: Great times are not coming (?) Christophe Hezode, Helene Fontaine, Yoann Barthe, Fabrice Carrat, Jean-Pierre Bronowicki PII: S0-()00-
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More informationBaseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis
Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis Georg Dultz 1, Martin Seelhof 1, Eva Herrmann 2, Martin-Walter Welker
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationTHE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O.
THE CHANGING LANDSCAPE OF HEPATITIS INFECTION Michael E. Herman D.O. What s New? For Primary Care Providers Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationChronic hepatitis C virus (HCV) infection is the most common
Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients Duminda Suraweera, MD, Vinay Sundaram, MD, MSc, and Sammy Saab, MD, MPH Dr Suraweera is a resident in the Department of Medicine
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationTreatment of Recurrent HCV Infection following Liver Transplantation
Hepatitis C Online PDF created June 27, 2018, 6:09 am Treatment of Recurrent HCV Infection following Liver Transplantation This is a PDF version of the following document: Module 6: Treatment of Special
More informationTreatment of Hepatitis C in Liver Transplant Patients: Interferon Out, Direct Antiviral Combos In
LIVER TRANSPLANTATION 21:423 434, 2015 REVIEW Treatment of Hepatitis C in Liver Transplant Patients: Interferon Out, Direct Antiviral Combos In Jennifer C. Price and Norah A. Terrault Department of Medicine,
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 5
National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationUnderstudied treatment populations: manage with care. Massimo Puoti Infectious Diseases Dept. AO Ospedale Niguarda Ca Granda Milan, Italy
Understudied treatment populations: manage with care Massimo Puoti Infectious Diseases Dept. AO Ospedale Niguarda Ca Granda Milan, Italy Understudied treatment populations Cirrhotics Data from registrative
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationK For patients who have never been tested for HCV, it is. K It is suggested that HCV-infected patients not previously
http://www.kidney-international.org & 2008 DIGO Guideline 4: Management of HCV-infected patients before and after kidney transplantation idney International (2008) 73 (Suppl 109), S53 S68; doi:10.1038/ki.2008.87
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationBruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University
Bruce A. Luxon, MD, PhD, FACG Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University Dr. Luxon is on the speakers p bureau
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationHepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni)
Hepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni) Prof. Dr. Markus Cornberg Klinik für Gastroenterologie, Hepatologie und Endokrinologie Antalya, 13.05.2016 Markus Cornberg, Hannover
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationBible Class: HCV Infection
Bible Class: HCV Infection PD Dr. Dr. med. Nasser Semmo UVCM, Hepatology What is the HCV prevalence and incidence? 2 HCV Prevalence Worldwide about 120-210 Mio. infected with HCV, about 9 Mio. in Europe,
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationDirectly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: A Flood of Opportunity
American Journal of Transplantation 2014; 14: 994 1002 Wiley Periodicals Inc. Minireview C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12714
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationTreatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience)
Korean Association of HBP Surgery President: Dong Wook Choi, MD, PhD, Samsung Medical Center Session : 09:50-10:50, 2 nd /3, Apr 27, 2013 Venue: Lotte Hotel, Jeju Island, Korea Session: Prevention of original
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationQUANTITATIVE HEPATITIS C VIRUS (HCV) RNA
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:
More informationa series of fact sheets written by experts in the field of liver disease HCV DISEASE PROGRESSION
www.hcvadvocate.org HCSP FACT SHEET Foreword Over years or decades, chronic hepatitis C virus (HCV) infection can progress to severe liver problems including cirrhosis and hepatocellular carcinoma (HCC).
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More information